Spots Global Cancer Trial Database for Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Official Title: A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Study ID: NCT01379807
Interventions
Study Description
Brief Summary: The clinical hypothesis of this study is that the addition of Panitumumab to the first line treatment combination of docetaxel plus cisplatin will provide benefit to patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Arquitecto Mercide, Ferrol, La Coruña, Spain
Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, La Coruña, Spain
Complejo Hospitalario Universitario de Vigo (Xeral Cies), Vigo, Pontevedra, Spain
Policlínica de Vigo S.A., Vigo, Pontevedra, Spain
Complejo Hospitalario Universitario de A Coruña, La Coruña, , Spain
Centro Oncológico de Galícia, La Coruña, , Spain
Hospital Universitario Lucus Augusti, Lugo, , Spain
Complejo Hospitalario Ourense, Ourense, , Spain
Hospital de Pontevedra, Pontevedra, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
